WaveMan
WaveMan · Company
STEX · Streamex Corp.
> Search tickers & screens ⌘K
LIVE
← All companies

STEX Streamex (STEX) Insider Trading, Ownership & Congress Trades

Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0001530766
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
29
13F, latest reported quarter

What the filings say about STEX

Insiders, 180 days
-$3.0K net sold
2 buyers · 2 sellers · 0% of sales under a 10b5-1 plan

Streamex insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Streamex Corp. insiders sold a net $3.0K of stock across 31 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Williams Mitchell Young
Chief Investment Officer
SELL
2026-10-07 SECtraded 2026-10-01
65,538
$35.2K
-13.6%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Jun 1, 2026.
  • The trade is 2.3% of the 2,820,276 shares held after it.
  • 1 other insider sold within 30 days.
  • 29 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Investment Officer Williams Mitchell Young sold about $35.2K of STEX on Oct 1, 2026; 1 other insider sold within 30 days and 29 funds added in the latest 13F quarter.
Plummer Christine Marie
Chief Financial Officer
SELL
2026-10-07 SECtraded 2026-10-01
13,344
$7.2K
-13.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Apr 15, 2026.
  • The trade is 2.9% of the 461,645 shares held after it.
  • 1 other insider sold within 30 days.
  • 29 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Plummer Christine Marie sold about $7.2K of STEX on Oct 1, 2026; 1 other insider sold within 30 days and 29 funds added in the latest 13F quarter.
Lekstrom Morgan Lee
Interim Executive Chairman
BUY
2026-06-15 SECtraded 2026-06-12
25,000
$25.2K
-55.8%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (12 buys, 1 sale), the last on May 28, 2026.
  • -69.4% median (-58.6% mean) 90-day return after 9 previous buys.
  • The trade is 7.5% of the 334,500 shares held after it.
  • 1 other insider bought within 30 days.
  • 29 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Interim Executive Chairman Lekstrom Morgan Lee bought about $25.2K of STEX on Jun 12, 2026; 1 other insider bought within 30 days and 29 funds added in the latest 13F quarter.
Lekstrom Morgan Lee
Interim Executive Chairman
BUY
2026-06-15 SECtraded 2026-06-12
25,000
$24.5K
-55.8%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (12 buys, 1 sale), the last on May 28, 2026.
  • -69.4% median (-58.6% mean) 90-day return after 9 previous buys.
  • The trade is 7.0% of the 359,500 shares held after it.
  • 1 other insider bought within 30 days.
  • 29 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Interim Executive Chairman Lekstrom Morgan Lee bought about $24.5K of STEX on Jun 12, 2026; 1 other insider bought within 30 days and 29 funds added in the latest 13F quarter.
Williams Mitchell Young
Chief Investment Officer
SELL
2026-06-02 SECtraded 2026-06-01
23,810
$25.0K
-59.2%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on May 1, 2026.
  • The trade is 0.8% of the 3,013,838 shares held after it.
  • No other insider sold within 30 days.
  • 29 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Investment Officer Williams Mitchell Young sold about $25.0K of STEX on Jun 1, 2026; 29 funds added in the latest 13F quarter.
31 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 26 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$3.0K over 180 days
-$42.4K over 90 days
more than 62% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
29 funds bought in last quarter
below 67% of Medical Devices
Revenue
+122.2% year over year
more than 94% of Medical Devices
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
8.3% of the float short (float per yahoo 2026-10-26) · 5.7 days to cover · settled 2026-09-30
more than 72% of Medical Devices
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 7 in the prior 90
Why it matters
The absence is the signal: 7 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Oct 7Chief Investment Officer Williams Mitchell Young sold $35.2K (Oct 1)
Oct 7Chief Financial Officer Plummer Christine Marie sold $7.2K (Oct 1)

Watch STEX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-90.8%12M
-92%-61%-29%+3%2025-102025-122026-022026-042026-062026-082026-10 2026-01-23 · GIUSTRA FRANK bought $3.0M2026-02-04 · GIUSTRA FRANK bought $317.0K2026-05-01 · Williams Mitchell Young sold $208.5K2026-01-23 · Williams Mitchell Young bought $156.1K2026-01-23 · Lekstrom Morgan Lee bought $147.1K2026-01-23 · Lekstrom Morgan Lee bought $128.3K2026-01-26 · Lekstrom Morgan Lee bought $75.9K2026-02-03 · Lekstrom Morgan Lee bought $71.9K2026-05-21 · Lekstrom Morgan Lee bought $56.1K2026-05-21 · Lekstrom Morgan Lee bought $55.1K2026-02-18 · Lekstrom Morgan Lee bought $50.0K2026-05-28 · Lekstrom Morgan Lee bought $50.0K2026-05-21 · Lekstrom Morgan Lee bought $41.9K2026-10-01 · Williams Mitchell Young sold $35.2K2026-04-14 · McPhie Karl Henry Michael sold $32.8K2026-06-12 · Lekstrom Morgan Lee bought $25.2K2025-11-21 · Lekstrom Morgan Lee bought $25.1K2026-06-01 · Williams Mitchell Young sold $25.0K2026-06-12 · Lekstrom Morgan Lee bought $24.5K2026-05-21 · Marciano Anthony Mark bought $20.1K2026-01-27 · Lekstrom Morgan Lee bought $17.2K2026-04-14 · Lekstrom Morgan Lee sold $13.7K2026-04-13 · Plummer Christine Marie sold $12.0K2026-01-29 · Lekstrom Morgan Lee bought $9.2K2026-10-01 · Plummer Christine Marie sold $7.2K2026-04-15 · Plummer Christine Marie sold $2.8K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns STEX: institutional holders (13F)

13F holdings, latest reported quarter
Legacy Wealth Managment, LLC/ID
6,530,074 sh
$5.6M
VANGUARD CAPITAL MANAGEMENT LLC
3,831,200 sh
$3.3M
Yorkville Advisors Global, LP
3,750,000 sh
$3.2M
GEODE CAPITAL MANAGEMENT, LLC
1,257,054 sh
$1.1M
BlackRock, Inc.
933,112 sh
$793.4K

Congress trades in STEX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

STEX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

STEX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Flex Small Cap Index Fund
$13.3K position · as of 2026-07-31
0.0%
Fidelity Extended Market Index Fund
$678.6K position · as of 2026-05-31
0.0%
Fidelity ZERO Extended Market Index Fund
$28.4K position · as of 2026-07-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$1.0M position · as of 2026-06-30
0.0%
VIP Extended Market Index Portfolio
$5.1K position · as of 2026-06-30
0.0%
Goldman Sachs Absolute Return Tracker Fund
$52.3K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Kenneth L. Londoner, and Anthony Amato
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$2.4M
$8.7M
$240.6K
-69%
n/a
2023
$1.8M
$1.8M
$737.8K
+13%
n/a
2022
$1.7M
$1.7M
$723.4K
-81%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $3.0K sold by insiders over 180 days, 29 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

STEX financials

Revenue growth
+122.2%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$30.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-705.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-371.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-127.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-59.2%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/a$40.0K$18.0K$286.0K
Gross profitn/an/a$18.0K$229.0K
Operating income-$71.1M-$12.9M-$28.5M-$27.3M
Net income-$462.8M-$10.3M-$29.0M-$27.1M
EPS (diluted)-9.65-0.75-3.95-6.33
Operating cash flow-$10.4M-$4.8M-$17.3M-$21.7M
Cash$20.3Mn/a$200.0K$400.0K
SEC XBRL, fiscal years, as known on 2026-10-28

STEX Stock Sonar score 5/7 axes

Find similar shapesCompare

STEX ranks highest on growth (94th percentile) and insider conviction (67th), and lowest on profitability (7th), among Medical Devices peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
7
Inputs
  • Return on equity-705.4% · 3 pct, sector of 183
  • Return on assets-371.9% · 3 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-127.8% · 14 pct, sector of 188
Growth
94
Inputs
  • Revenue growth, YoY+122.2% · 94 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
67
Inputs
  • Net Form 4 buying (codes P and S), 180d-$3K · 60 pct, sector of 140
  • Insider buyers, 180d2 · 74 pct, sector of 142
Institutional and government
33
Inputs
  • Funds adding, latest quarter29 · 33 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
15
Inputs
  • Short interest, % of float+8.3% · 28 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+42.6% · 3 pct, sector of 198
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

STEX filings, in plain words

Are Streamex insiders buying or selling STEX?

In the 180 days to 2026-10-28, Streamex insiders were net sellers, a net $3.0K: $272.9K of purchases and $275.9K of sales reported on Form 4, by 2 buyers and 2 sellers.

Read the full summary

In the 180 days to 2026-10-28, Streamex insiders were net sellers of STEX, a net $3.0K across purchases and sales reported on Form 4 by 2 buyers and 2 sellers. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies